PUBLISHER: The Business Research Company | PRODUCT CODE: 1760719
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760719
Spatial genomics and transcriptomics encompass techniques that map the spatial distribution of gene expression and genetic information within tissues, enabling researchers to examine how cells interact within their native environments and contribute to biological processes or diseases. These methods offer high-resolution insights into gene activity at specific tissue locations, revealing cellular heterogeneity, disease mechanisms, and potential therapeutic targets.
The primary product types in spatial genomics and transcriptomics include instruments, consumables, and software. Instruments are devices or tools used for scientific research, including the investigation of natural phenomena and theoretical studies. These tools incorporate technologies such as spatial transcriptomics, sequencing-based methods, immunohistochemistry (IHC), microscopy-based RNA imaging techniques, and spatial genomics. They are applied in diagnostics, translational research, drug discovery and development, single-cell analysis, cell biology, and more. The main end users include pharmaceutical and biotechnology companies, contract research organizations, and academic and research institutes.
The spatial genomics and transcriptomics market research report is one of a series of new reports from The Business Research Company that provides spatial genomics and transcriptomics market statistics, including spatial genomics and transcriptomics industry global market size, regional shares, competitors with a spatial genomics and transcriptomics market share, detailed spatial genomics and transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the spatial genomics and transcriptomics industry. This spatial genomics and transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The spatial genomics and transcriptomics market size has grown rapidly in recent years. It will grow from $1.51 billion in 2024 to $1.70 billion in 2025 at a compound annual growth rate (CAGR) of 12.7%. The growth during the historic period can be attributed to the emergence of single-cell genomics, increased funding for cancer research, expansion of bioinformatics infrastructure, rising demand for precision medicine, and advancements in pharmaceutical research and development.
The spatial genomics and transcriptomics market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The anticipated growth in the forecast period is driven by the increasing need for early disease detection, a rise in biomarker discovery, regulatory support for advanced diagnostics, growing adoption of personalized medicine, and continued expansion in cancer research. Key trends expected during this period include improvements in sequencing technologies, integration of AI and machine learning, development of innovative data processing and visualization tools, advancements in data storage and analysis solutions, and increased collaborations and consortia.
The growing adoption of personalized medicine is expected to drive the growth of the spatial genomics and transcriptomics market in the coming years. Personalized medicine is an approach to healthcare that tailors treatment plans to individual patients based on their genetic makeup, lifestyle, and environmental factors, enhancing treatment effectiveness and minimizing side effects. The increasing demand for personalized medicine is fueled by advancements in genetic research, which enable more precise treatments customized to an individual's unique genetic profile, leading to improved patient outcomes. Spatial genomics and transcriptomics play a key role in personalized medicine by identifying the precise location and activity of genes within tissues, allowing for targeted, individualized treatment strategies based on a patient's molecular landscape. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based nonprofit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant increase from the six approvals in 2022. As a result, the rising adoption of personalized medicine is driving the growth of the spatial genomics and transcriptomics market.
Leading companies in the spatial genomics and transcriptomics market are focusing on developing innovative solutions, such as spatial transcriptomics technologies, to deepen our understanding of gene expression in the context of tissue architecture. Spatial transcriptomics refers to advanced techniques that map gene expression across tissue samples while maintaining their spatial context, allowing researchers to study the distribution and location of RNA molecules within tissues. For instance, in February 2025, Illumina Inc., a U.S.-based biotechnology company, launched pioneering spatial transcriptomics technology that significantly enhances the ability to map and analyze gene expression within complex tissues at cellular resolution. This technology offers a capture area nine times larger and four times higher resolution than existing methods, enabling unbiased, whole-transcriptome profiling with high sensitivity. It is compatible with Illumina's NextSeq and NovaSeq sequencers and integrated into the Illumina Connected Multiomics platform, facilitating comprehensive multiomic data analysis.
In April 2024, Bruker Corporation, a U.S.-based manufacturer of scientific instruments and analytical solutions, acquired NanoString Technologies for an undisclosed amount. This acquisition aims to enhance Bruker's spatial biology portfolio by integrating NanoString's gene expression and spatial transcriptomics solutions. This move positions Bruker as a market leader, fostering innovation, revenue growth, and long-term value in the post-genomic era. NanoString Technologies is a U.S.-based biotechnology company specializing in spatial genomics and transcriptomics solutions.
Major players in the spatial genomics and transcriptomics market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Bio-Techne Corporation, 10x Genomics Inc., Standard BioTools Inc., Akoya Biosciences Inc., Seven Bridges Genomics, Vizgen Inc., Lunaphore Technologies SA., Parse Biosciences, Indica Labs Inc., Resolve Biosciences GmbH., RareCyte Inc., Ionpath Inc., Dovetail Genomics, S2 Genomics Inc., and BioSpyder Technologies Inc.
North America was the largest region in the spatial genomics and transcriptomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spatial genomics and transcriptomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the spatial genomics and transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The spatial genomics and transcriptomics market includes revenues earned by entities by providing services such as spatial gene expression profiling, single-cell RNA sequencing, spatially resolved transcriptome analysis, cancer and disease research, and spatial epigenomics. The market value includes the value of related goods sold by the service provider or included within the service offering. The spatial genomics and transcriptomics market also includes sales of spatial transcriptomics platforms, imaging systems, and sequencing instruments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Spatial Genomics And Transcriptomics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on spatial genomics and transcriptomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for spatial genomics and transcriptomics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The spatial genomics and transcriptomics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.